NCM
AQST icon

Nantahala Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Nantahala Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-600,000
Closed -$3.35M – 156
2025
Q3 		$3.35M Buy
+600,000
New +$2.59M 0.12% 118

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nantahala Capital Management's AQST Position: Q4 2025 in Review

Nantahala Capital Management sold out of Aquestive Therapeutics (AQST) in Q4 2025, closing a stake of 600,000 shares — an estimated $3.35M sold.

Nantahala Capital Management first reported a position in AQST in Q3 2025 and held it in 1 quarter. The position peaked at $3.35M in Q3 2025. 177 funds tracked by Wall St. Rank hold AQST as of Q4 2025.

  • Nantahala Capital Management reported no remaining Aquestive Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 600,000 Aquestive Therapeutics shares in Q4 2025, an estimated $3.35M.
  • Nantahala Capital Management first reported a position in Aquestive Therapeutics in Q3 2025 and held it in 1 quarter.
  • Nantahala Capital Management's Aquestive Therapeutics position peaked at $3.35M in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2025.

Based on Nantahala Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.